Author

Morgan Leichter

Institution: Takeda Oncology (United States)

Observed institution: Takeda Oncology (United States)

OpenAlex ID: A5005877642

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

2019 · Shaji K. Kumar, Robert F. Cornell, et al. · Blood · 7

Works count: 1

Citation count: 7

H-index: 1

I10-index: